Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group
Abstract
Monthly administration of 750 mg/kg of RSV-IGIV was safe and well tolerated and was effective in reducing the incidence and total days of both RSV hospitalization and overall respiratory hospitalization in infants with a history of prematurity or bronchopulmonary dysplasia or both.
Keywords
respiration
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
female
male
Infant
newborn
Clinical Trial
Randomized Controlled Trial
Double-Blind Method
immunoglobulins
intravenous / therapeutic use*
length of stay
placebos
Artificial
respiratory syncytial virus infections / prevention & control*
hospitalization
premature*
respiratory syncytial virus infections / complications*
bronchopulmonary dysplasia / complications*
pmid:8989345
doi:10.1542/peds.99.1.93
respiratory syncytial virus infections / rehabilitation
Access
Citation
ID:
120846
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
120846
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet
